MCID: LRY018
MIFTS: 51

Laryngeal Squamous Cell Carcinoma

Categories: Cancer diseases, Oral diseases, Rare diseases, Respiratory diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Laryngeal Squamous Cell Carcinoma

MalaCards integrated aliases for Laryngeal Squamous Cell Carcinoma:

Name: Laryngeal Squamous Cell Carcinoma 11 53 14 16
Squamous Cell Carcinoma of Head and Neck 43
Squamous Cell Carcinoma of the Larynx 58
Epidermoid Carcinoma of the Larynx 11
Squamous Cell Carcinoma of Larynx 11

Characteristics:


Prevelance:

Squamous Cell Carcinoma of the Larynx: 1-9/100000 (Europe) 58

Age Of Onset:

Squamous Cell Carcinoma of the Larynx: Adolescent,Adult,Childhood,Elderly 58

Classifications:



External Ids:

Disease Ontology 11 DOID:2876
MeSH 43 D000077195
NCIt 49 C4044
SNOMED-CT 68 707358000
Orphanet 58 ORPHA494550
UMLS 71 C0280324

Summaries for Laryngeal Squamous Cell Carcinoma

Orphanet: 58 A rare head and neck tumor characterized by a malignant epithelial neoplasm with evidence of squamous differentiation, most commonly located in the supraglottis or glottis. The tumor can spread directly to adjacent structures or metastasize via lymphatic and blood vessels to regional lymph nodes, or lung, liver, and bones, respectively. Primary risk factors are tobacco smoking and (to a lesser extent) alcohol consumption. Patients may present with hoarseness, dyspnea, stridor, dysphagia, hemoptysis, or odynophagia.

MalaCards based summary: Laryngeal Squamous Cell Carcinoma, also known as squamous cell carcinoma of head and neck, is related to laryngeal benign neoplasm and larynx cancer. An important gene associated with Laryngeal Squamous Cell Carcinoma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are TNFR1 Pathway and Endometrial cancer. The drugs Ethanol and Petrolatum have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and liver, and related phenotypes are neoplasm and no phenotypic analysis

Disease Ontology: 11 A laryngeal carcinoma that has material basis in squamous cells.

Related Diseases for Laryngeal Squamous Cell Carcinoma

Diseases related to Laryngeal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 461)
# Related Disease Score Top Affiliating Genes
1 laryngeal benign neoplasm 32.8 TP53 EGFR CDKN2A CCND1
2 larynx cancer 32.6 TP53 MIR21 EGFR CCND1 BCL2
3 head and neck cancer 32.0 TP53 PTEN MIR21 EGFR CDKN2A CCND1
4 papilloma 31.9 TP53 PTEN EGFR CDKN2A CCND1 BCL2
5 hypopharynx cancer 31.7 TP53 EGFR CDKN2A CCND1 BCL2
6 squamous cell carcinoma 31.5 TP53 TNFRSF10B PTEN NEAT1 MALAT1 ING1
7 keratinizing squamous cell carcinoma 31.4 TP53 EGFR CDKN2A
8 carcinosarcoma 31.2 TP53 PTEN EGFR CDKN2A
9 suppression of tumorigenicity 12 31.2 TP53 PTEN EGFR CDKN2A
10 lip and oral cavity cancer 31.2 TP53 MIR21 EGFR CDKN2A CCND1
11 gastroesophageal reflux 31.2 TP53 EGFR CCND1 BCL2
12 squamous cell carcinoma, head and neck 31.1 TP53 TNFRSF10B PTEN MIR21 ING1 HOTAIR
13 actinic keratosis 31.1 TP53 EGFR CDKN2A BCL2
14 b-cell lymphoma 31.0 TP53 MALAT1 HOTAIR CDKN2A CCND1 BCL2
15 lymphoma 31.0 TP53 EGFR CDKN2A CCND1 BCL2
16 neurofibroma 31.0 TP53 PTEN EGFR CDKN2A
17 chronic lymphocytic leukemia/small lymphocytic lymphoma 31.0 TP53 CCND1 BCL2
18 basal cell nevus syndrome 31.0 TP53 PTEN CCND1 BCL2
19 keratoacanthoma 31.0 TP53 EGFR BCL2
20 paraganglioma 31.0 EGFR CDKN2A CCND1 BCL2
21 human papillomavirus infectious disease 30.9 TP53 PTEN MIR21 EGFR CDKN2A CCND1
22 oropharynx cancer 30.9 TP53 PTEN MIR21 EGFR CDKN2A CCND1
23 salivary gland carcinoma 30.9 TP53 EGFR CDKN2A
24 glottis squamous cell carcinoma 30.9 PTEN EGFR
25 verrucous carcinoma 30.9 TP53 EGFR CDKN2A
26 leukemia, chronic lymphocytic 30.9 TP53 PTEN NEAT1 MIR21 EGFR CDKN2A
27 suppressor of tumorigenicity 3 30.9 TP53 CDKN2A BCL2
28 mixed cell type cancer 30.9 TP53 PTEN EGFR CDKN2A
29 keratosis 30.9 TP53 EGFR CDKN2A BCL2
30 liposarcoma 30.9 TP53 PTEN CDKN2A CCND1 BCL2
31 leiomyosarcoma 30.8 TP53 CDKN2A CCND1 BCL2
32 malignant peripheral nerve sheath tumor 30.8 TP53 EGFR CDKN2A
33 adenoid cystic carcinoma 30.8 TP53 PTEN EGFR CDKN2A CCND1 BCL2
34 small cell carcinoma 30.8 TP53 PTEN EGFR
35 thymoma 30.8 TP53 EGFR CDKN2A BCL2
36 peripheral nervous system disease 30.8 TP53 PTEN MIR21 EGFR CDKN2A CCND1
37 thyroid gland follicular carcinoma 30.8 TP53 PTEN CCND1
38 esophagus adenocarcinoma 30.7 TP53 MIR21 EGFR CDKN2A CCND1
39 colonic benign neoplasm 30.7 TP53 PTEN MIR21 EGFR CDKN2A CCND1
40 skin carcinoma 30.7 TP53 PTEN MIR21 EGFR CDKN2A CCND1
41 gastrointestinal stromal tumor 30.7 TP53 PTEN HOTAIR EGFR CDKN2A CCND1
42 small cell cancer of the lung 30.7 TP53 PTEN MIR21 MALAT1 HOTAIR EGFR
43 cervix carcinoma 30.7 TP53 PTEN MIR21 HOXA11-AS EGFR CDKN2A
44 skin disease 30.6 TP53 PTEN MIR21 EGFR CDKN2A CCND1
45 basal cell carcinoma 30.6 TP53 PTEN EGFR CDKN2B-AS1 CDKN2A BCL2
46 lung squamous cell carcinoma 30.6 TP53 PTEN EGFR CDKN2A CCAT1
47 intrahepatic cholangiocarcinoma 30.6 TP53 EGFR CCAT1
48 breast adenocarcinoma 30.6 TP53 PTEN H19 EGFR CDKN2A CCND1
49 adenocarcinoma 30.6 TP53 PTEN MALAT1 H19 EGFR CDKN2A
50 skin squamous cell carcinoma 30.5 TP53 PTEN MIR21 HOTAIR EGFR CDKN2A

Graphical network of the top 20 diseases related to Laryngeal Squamous Cell Carcinoma:



Diseases related to Laryngeal Squamous Cell Carcinoma

Symptoms & Phenotypes for Laryngeal Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Laryngeal Squamous Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.56 BCL2 CCND1 CDKN2A EGFR ING1 PTEN
2 no phenotypic analysis MP:0003012 9.17 CDKN2A EGFR HOTAIR HOXA11-AS MALAT1 TNFRSF10B

Drugs & Therapeutics for Laryngeal Squamous Cell Carcinoma

Drugs for Laryngeal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 345)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Petrolatum Approved, Investigational Phase 4 8009-03-8
3
Mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7 4240 441336
4
Titanium dioxide Approved Phase 4 13463-67-7
5
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758 135400182
6
Mitomycin Approved Phase 4 50-07-7 5746
7 Anti-Allergic Agents Phase 4
8 Anti-Bacterial Agents Phase 4
9 Antibiotics, Antitubercular Phase 4
10
Dapsone Approved, Investigational Phase 3 80-08-0 2955
11
Minocycline Approved, Investigational Phase 3 10118-90-8, 13614-98-7 54675783 5281021
12
Cobalt Approved, Experimental, Withdrawn Phase 3 7440-48-4 104729
13
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
14
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
15
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2 23431961
16
Palbociclib Approved, Investigational Phase 3 571190-30-2 5330286
17
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
18
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
19
Pentetic acid Approved Phase 3 67-43-6
20
Melatonin Approved, Nutraceutical, Vet_approved Phase 3 73-31-4 896
21
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
22 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
23
Zalutumumab Investigational Phase 3 667901-13-5
24
Tirapazamine Investigational Phase 3 27314-97-2 135413511
25
Nimorazole Investigational Phase 3 6506-37-2 23009
26 Endostatins Phase 3
27 Antirheumatic Agents Phase 3
28 1,2-diaminocyclohexaneplatinum II citrate Phase 2, Phase 3
29 Citrate Phase 2, Phase 3
30 Lugol's solution Phase 3
31 Anti-Infective Agents Phase 3
32 Chelating Agents Phase 3
33 Antiprotozoal Agents Phase 3
34 Antiparasitic Agents Phase 3
35 Radiopharmaceuticals Phase 3
36 Anticoagulants Phase 3
37 Blood Substitutes Phase 3
38 Plasma Substitutes Phase 3
39 Technetium Tc 99m Pentetate Phase 3
40 Dextrans Phase 3
41 Orange Approved Phase 2
42
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
43
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
44
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
45
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
46
Metformin Approved Phase 1, Phase 2 1115-70-4, 657-24-9 4091
47
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
48
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
49
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
50
Acalabrutinib Approved, Investigational Phase 2 1420477-60-6 71226663 71226662

Interventional clinical trials:

(show top 50) (show all 1129)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor Unknown status NCT04766827 Phase 4 albumin-bound paclitaxel
2 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
3 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
4 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
5 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
6 A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10). Active, not recruiting NCT04489888 Phase 4 Pembrolizumab;Carboplatin;Paclitaxel
7 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
8 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Withdrawn NCT03388931 Phase 4
9 SCT-I10A Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase III, Multicenter, Randomized, Double-blinded Trial Unknown status NCT04146402 Phase 3 SCT-I10A+chemo;Placebos+chemo
10 Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma Unknown status NCT01874171 Phase 3 Cisplatin;Cetuximab
11 Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy(Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ) Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(R/M SCCHN) Unknown status NCT03855384 Phase 3 TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU);placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
12 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
13 Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Unknown status NCT00999700 Phase 3 docetaxel - cisplatin - 5-fluorouracil;cetuximab;cisplatin
14 Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head & Neck: a Randomized Multi-center Phase III Clinical Trial Unknown status NCT02923258 Phase 2, Phase 3 Docetaxel;Cisplatinum
15 A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
16 A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients Completed NCT02551159 Phase 3 5-fluorouracil (5FU);Cisplatin;Carboplatin
17 Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma Completed NCT01864850 Phase 3
18 Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT04137627 Phase 3 Melatonin 20 MG Oral Capsule;Placebo oral capsule
19 An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02741570 Phase 3 Cetuximab/Erbitux;Cisplatin/Platinol;Carboplatin/Paraplatin;Fluorouracil/Adrucil
20 Relationship Between Changes in Body Composition and Supplementation With EPA in Patients Diagnosed With Squamous Cell Carcinoma of Head and Neck Locally Advanced (Stage III-IVb) Completed NCT02715596 Phase 3
21 Phase III Randomized Comparison of Radiotherapy Fractionation in Advanced Squamous Cell Carcinoma of the Head and Neck: Twice-Daily Hyperfractionation vs Split-Course Accelerated Hyperfractionation vs Accelerated Fractionation With Concomitant Boost vs Standard Fractionation Completed NCT00771641 Phase 3
22 An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02105636 Phase 3 Nivolumab;Cetuximab;Methotrexate;Docetaxel
23 A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) Completed NCT01950689 Phase 3 Nimorazole
24 Phase I/II Trial of Erlotinib, Radiation Therapy, and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck Completed NCT00442455 Phase 3 Erlotinib chlorhydrate;Cisplatin
25 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT03349710 Phase 3 Cetuximab;Cisplatin
26 DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck Completed NCT00496652 Phase 3 Zalutumumab
27 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
28 Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00122460 Phase 3 Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU);Platinum (Cisplatin or Carboplatin) + 5-FU
29 Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomized Phase III Factorial Study. Completed NCT01086826 Phase 3 RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
30 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
31 Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer Completed NCT00174837 Phase 3 Tirapazamine;Cisplatin
32 Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety of Cetuximab When Given in Combination With Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed NCT01012258 Phase 3
33 A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT02383966 Phase 3 Cetuximab;Cisplatin/Carboplatin;5-fluorouracil
34 Phase III Placebo-Controlled Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201279 Phase 3 13-cis Retino Acid
35 A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck Completed NCT00206219 Phase 3 Gefitinib;methotrexate
36 Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
37 An Open-label, Randomized, Parallel-group, Multicenter Study of Neoadjuvant Docetaxel(Taxotere®) Plus Cisplatin Plus 5-fluorouracil Versus Neoadjuvant Cisplatin Plus 5-fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck Completed NCT00995293 Phase 3 DOCETAXEL;CISPLATIN;5-FLUOROURACIL
38 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02369874 Phase 3 MEDI4736;MEDI4736 + Tremelimumab;Standard of Care
39 Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy Completed NCT02347332 Phase 3 Vinflunine;Methotrexate
40 Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux Completed NCT00609284 Phase 3 cetuximab;Carboplatin, 5FU concomitant
41 Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma Completed NCT01542931 Phase 2, Phase 3 TPF induction chemotherapy
42 A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02 Completed NCT01427478 Phase 3 AFATINIB;Placebo of AFATINIB
43 Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety Profile of Cetuximab When Given in Combination With Chemotherapy for the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck in Asian Subjects Completed NCT01177956 Phase 3 Cisplatin;5-Fluorouracil
44 Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck Recruiting NCT01810913 Phase 2, Phase 3 Atezolizumab;Cisplatin;Docetaxel
45 A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers Recruiting NCT05063552 Phase 2, Phase 3 Carboplatin;Cisplatin;Docetaxel
46 Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Recruiting NCT05050162 Phase 2, Phase 3 Cisplatin
47 A Phase 3, Randomized, Open-label Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Recruiting NCT03815903 Phase 3 Induction chemotherapy
48 Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer Recruiting NCT04333537 Phase 2, Phase 3 Imaging Agent
49 A Phase 3, Prospective,Multicenter, Randomized Open-Label Trial to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Chemotherapy Followed By Surgery Versus Up-Front Surgery as Treatment for Resectable Head And Neck Squamous Cell Carcinoma Recruiting NCT05582265 Phase 3 Tislelizumab(neoadjuvant);Cisplatin (neoadjuvant);Nab-paclitaxel (neoadjuvant);Cisplatin(adjuvant);Tislelizumab(adjuvant)
50 Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck Recruiting NCT01893307 Phase 2, Phase 3

Search NIH Clinical Center for Laryngeal Squamous Cell Carcinoma

Cochrane evidence based reviews: squamous cell carcinoma of head and neck

Genetic Tests for Laryngeal Squamous Cell Carcinoma

Anatomical Context for Laryngeal Squamous Cell Carcinoma

Organs/tissues related to Laryngeal Squamous Cell Carcinoma:

MalaCards : Lung, Lymph Node, Liver, T Cells, Myeloid, Salivary Gland, Breast

Publications for Laryngeal Squamous Cell Carcinoma

Articles related to Laryngeal Squamous Cell Carcinoma:

(show top 50) (show all 3181)
# Title Authors PMID Year
1
GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. 53 62
19922706 2010
2
Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. 53 62
19741544 2010
3
Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. 53 62
19669840 2009
4
EGFR immunoexpression and peripheral blood cytokine secretion as potential biomarkers of tumor behavior in laryngeal squamous cell carcinoma. 53 62
19789511 2009
5
Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. 53 62
19375219 2009
6
[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. 53 62
19813623 2009
7
[The expressions and correlation of AQP1 and VEGF in laryngeal squamous cell carcinoma]. 53 62
19670620 2009
8
Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. 53 62
19148533 2009
9
[The expression of Galectin-3 and VEGF in laryngeal squamous cell carcinoma]. 53 62
19452726 2009
10
p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. 53 62
18607952 2009
11
Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck. 53 62
19183379 2009
12
Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line. 53 62
18998509 2008
13
[hTERT promoter enhances the radiosensitivity to gene-radiation therapy of human laryngeal carcinoma transplanted in nude mice]. 53 62
19173799 2008
14
[Effect of CDK2 on proliferation in laryngeal squamous cell carcinoma]. 53 62
19166026 2008
15
[Study of the lymph node micrometastasis in patients with supraglottic carcinoma]. 53 62
19166031 2008
16
[Expression of angiopoietin-1,2 and its relationship with angiogenesis in laryngeal squamous cell carcinoma]. 53 62
19086654 2008
17
Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma. 53 62
18602381 2008
18
[Detection of Skp2 mRNA gene expression using fluorogenic probe quantitative RT-PCR method in laryngeal squamous cell carcinoma]. 53 62
18800682 2008
19
Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. 53 62
18509272 2008
20
Short hairpin ribonucleic acid targeting the telomerase catalytic unit of messenger ribonucleic acid significantly limits the growth of laryngeal squamous cell carcinoma in nude mice. 53 62
17592663 2008
21
Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis. 53 62
18357366 2008
22
[Expression of cyclin G1 in laryngeal squamous cell carcinoma and its clinicopathologic significance]. 53 62
18788592 2008
23
[Expression of Survivin, Caspase-3 and p53 in surgical margin of laryngeal squamous cell carcinoma and their relationship]. 53 62
18476631 2008
24
Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. 53 62
18787961 2008
25
Possible prognostic role of p53 expression in laryngeal squamous cell carcinoma of non-smokers, non-alcoholic patients. 53 62
18607961 2008
26
Expression of PTEN protein in patients with laryngeal squamous cell carcinoma. 53 62
17475427 2007
27
[Effects of HPV 16-E6/E7 oncogene on expression of vascular endothelial growth factor and matrix metalloproteinase 9 in human laryngeal squamous cell carcinoma cell line]. 53 62
18307884 2007
28
Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. 53 62
17974987 2007
29
Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis. 53 62
17712678 2007
30
[Expression and clinical significance of Endostatin, vascular endothelial growth factor and fibroblast growth factor basic-2 in laryngeal carcinoma]. 53 62
18051571 2007
31
[Expression and role of survivin in laryngeal squamous cell carcinoma and laryngeal papilloma in adults]. 53 62
17634026 2007
32
Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC). 53 62
17328665 2007
33
[Clinical significance and expression of FLIP and PTEN protein in laryngeal squamous cell carcinoma]. 53 62
17441421 2007
34
The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma. 53 62
17264532 2007
35
[Expression and clinical significance of matrix metalloproteinase-2 in laryngeal squamous cell carcinoma]. 53 62
17357514 2006
36
[Expression of telomerase reverse transcriptase and its relationship with expression of c-myc in laryngeal squamous cell carcinomas]. 53 62
17219990 2006
37
5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. 53 62
17207318 2006
38
Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis. 53 62
17094406 2006
39
Relation of glutathione S-transferase genotypes (GSTM1 and GSTT1) to laryngeal squamous cell carcinoma risk. 53 62
16938565 2006
40
Immunohistochemical estimation of cell cycle phase in laryngeal neoplasia. 53 62
16832409 2006
41
[Construction of recombinant adenovirus vector carrying cell cycle controlling gene-p14ARF]. 53 62
16845966 2006
42
[The investigation of STK15 gene amplification and overexpression in laryngeal squamous cell carcinoma]. 53 62
16767676 2006
43
[The relationship between hypermethylation of the PTEN promoter and laryngeal squamous cell carcinoma]. 53 62
16739377 2006
44
[The clinical significance of the expression of p63 gene in laryngeal squamous cell carcinoma]. 53 62
16646404 2006
45
Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance. 53 62
16711020 2006
46
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. 53 62
15965904 2006
47
Promoter hypermethylation of DNA repair gene MGMT in laryngeal squamous cell carcinoma. 53 62
16711019 2006
48
[Inhibitory effect of silencing hTERT gene by short hairpin RNA on growth of human laryngeal squamous cell carcinoma xenograft in nude mice]. 53 62
16405742 2006
49
Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. 53 62
16265652 2006
50
[The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma]. 53 62
16763427 2006

Variations for Laryngeal Squamous Cell Carcinoma

Expression for Laryngeal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Laryngeal Squamous Cell Carcinoma.

Pathways for Laryngeal Squamous Cell Carcinoma

Pathways related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 BCL2 CDKN2A EGFR PTEN TNFRSF10B TP53
2
Show member pathways
12.55 TP53 PTEN EGFR CDKN2A CCND1 BCL2
3 12.52 TP53 PTEN EGFR CDKN2A CCND1 BCL2
4
Show member pathways
12.37 TP53 PTEN CCND1 BCL2
5
Show member pathways
12.36 TP53 PTEN EGFR CCND1
6 12.2 PTEN EGFR CCND1 BCL2
7
Show member pathways
12.12 TP53 PTEN EGFR CCND1 BCL2
8
Show member pathways
12.06 TP53 PTEN CDKN2A CCND1
9
Show member pathways
12 BCL2 CCND1 PTEN TNFRSF10B TP53
10 11.9 TP53 PTEN EGFR CCND1 BCL2
11 11.85 TP53 CCND1 BCL2
12 11.83 BCL2 CCND1 PTEN TP53
13 11.79 TP53 PTEN CCND1 BCL2
14 11.76 TP53 TNFRSF10B PTEN EGFR BCL2
15 11.7 CDKN2A CCND1 BCL2
16 11.62 TP53 MIR21 CCND1
17 11.57 TP53 CDKN2A CCND1
18
Show member pathways
11.54 TP53 PTEN CCND1
19 11.54 TP53 PTEN CDKN2A CCND1
20 11.37 TP53 PTEN ING1 CDKN2A BCL2
21
Show member pathways
11.35 EGFR CCND1 BCL2
22 11.31 TP53 PTEN BCL2
23 11.23 TP53 TNFRSF10B PTEN
24 11.06 TP53 EGFR CDKN2A CCND1
25 11.01 TP53 TNFRSF10B BCL2
26
Show member pathways
10.95 TP53 CDKN2A BCL2
27 10.88 TP53 PTEN EGFR CDKN2A CCND1
28 10.36 TP53 BCL2

GO Terms for Laryngeal Squamous Cell Carcinoma

Biological processes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.21 BCL2 CDKN2A PTEN RRP1B SRA1 TNFRSF10B
2 negative regulation of cell population proliferation GO:0008285 10.1 TP53 PTEN MIR21 ING1 CDKN2A BCL2
3 negative regulation of cell growth GO:0030308 10.06 TP53 ING1 CDKN2A BCL2
4 regulation of cell cycle GO:0051726 10.05 TP53 PTEN CDKN2A CCND1 BCL2
5 cellular response to hypoxia GO:0071456 10.02 TP53 PTEN MALAT1 BCL2
6 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress GO:0070059 9.85 TP53 TNFRSF10B BCL2
7 B cell lineage commitment GO:0002326 9.8 TP53 BCL2
8 T cell lineage commitment GO:0002360 9.7 TP53 BCL2
9 positive regulation of apoptotic process GO:0043065 9.65 TP53 TNFRSF10B RRP1B MIR21 CDKN2A BCL2
10 response to UV-A GO:0070141 9.62 CCND1 EGFR
11 cell population proliferation GO:0008283 9.55 TP53 PTEN EGFR CCND1 BCL2
12 positive regulation of miRNA maturation GO:1903800 9.54 TP53 EGFR
13 negative regulation of mitotic cell cycle GO:0045930 9.43 TP53 MIR21 BCL2
14 negative regulation of superoxide dismutase activity GO:1901670 8.62 MIR21 H19

Sources for Laryngeal Squamous Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....